ProMIS Neurosciences (23J) Price & Analysis

Q: What was ProMIS Neurosciences’s price range in the past 12 months?

ProMIS Neurosciences lowest stock price was €5.68 and its highest was €22.00 in the past 12 months.

Q: What is ProMIS Neurosciences’s market cap?

ProMIS Neurosciences’s market cap is €64.70M.

Q: When is ProMIS Neurosciences’s upcoming earnings report date?

ProMIS Neurosciences’s upcoming earnings report date is Nov 18, 2026 which is in 22 days.

Q: How were ProMIS Neurosciences’s earnings last quarter?

ProMIS Neurosciences released its earnings results on Aug 13, 2026. The company reported -€1.142 earnings per share for the quarter, beating the consensus estimate of -€1.23 by €0.088.

Q: Is ProMIS Neurosciences overvalued?

According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does ProMIS Neurosciences pay dividends?

ProMIS Neurosciences does not currently pay dividends.

Q: What is ProMIS Neurosciences’s EPS estimate?

ProMIS Neurosciences’s EPS estimate is -1.11.

Q: How many shares outstanding does ProMIS Neurosciences have?

ProMIS Neurosciences has 8,967,693 shares outstanding.

Q: What happened to ProMIS Neurosciences’s price movement after its last earnings report?

ProMIS Neurosciences reported an EPS of -€1.142 in its last earnings report, beating expectations of -€1.23. Following the earnings report the stock price went up 3.333%.

Q: Which hedge fund is a major shareholder of ProMIS Neurosciences?

Currently, no hedge funds are holding shares in DE:23J

3 Followers

23J Stock Chart & Stats

€12.20

-€1.10(-9.40%)

At close: Jul 24 4:00 PM EDT

€12.20

-€1.10(-9.40%)

Day’s Range― - ―

52-Week Range€5.68 - €22.00

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€64.70M

Enterprise Value€66.85M

Total Cash (Recent Filing)€53.46M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta-0.07

Next Earnings

Nov 18, 2026

EPS Estimate

-1.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-16.89

Shares Outstanding8,967,693

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)-9.53

Price to Sales (P/S)0.00

P/FCF Ratio-0.43

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€38.32

Price Target Upside214.08% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-4.54

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance SheetReported zero debt reduces near-term solvency and interest-burden risk while the company funds clinical development. This cleaner leverage profile provides more financial flexibility than a highly indebted development-stage biotech, although it does not yet offset ongoing operating losses.

Encouraging PMN310 Safety SignalsThe favorable interim safety profile is strategically important in Alzheimer’s drug development because ARIA is a major limitation of some existing therapies. Lower observed safety burden could support broader clinical use if later data confirm the result and demonstrate efficacy.

Differentiated Alzheimer’s MechanismEarly biomarker reductions support the biological rationale for PMN310 and its oligomer-selective approach, including potential relevance for high-risk APOE4 carriers. If sustained in the full study, this could differentiate the program within Alzheimer’s therapeutics.

Bears Say

No Commercial RevenueThe absence of revenue confirms that PMN remains pre-commercial and dependent on successful clinical development before it can build an operating revenue base. This leaves financial performance highly exposed to trial outcomes, regulatory progress, and the ability to secure additional funding.

Persistent Cash BurnPersistent negative operating and free cash flow means ongoing research and operations are being funded externally rather than by the business. Continued burn can require repeated financing and may create dilution risk, particularly if development timelines extend or results disappoint.

Clinical Efficacy UnprovenThe current PMN310 readout supports safety and biomarker activity but does not establish clinical efficacy. Until the blinded study is unmasked and full 12-month results are available, the lead program remains exposed to substantial development uncertainty and outcome risk.

ProMIS Neurosciences News

ProMIS Neurosciences appoints Ivana Rubino as chief commercial officer

ProMIS Neurosciences (PMN) announced the appointment of Ivana Rubino as chief commercial officer, effective October 5. During her...

21d ago

PMN

BIIB

ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital

Roth Capital lowered the firm’s price target on ProMIS Neurosciences (PMN) to $29 from $30 and keeps a...

2M ago

PMN

BIIB

ProMIS Neurosciences reports Q2 EPS ($1.28), consensus ($1.90)

“The second quarter of 2026 was a pivotal period for ProMIS, as we continued to advance PRECISE-AD while...

2M ago

PMN

ProMIS Neurosciences price target raised to $100 from $69 at Guggenheim

Guggenheim raised the firm’s price target on ProMIS Neurosciences (PMN) to $100 from $69 and keeps a Buy...

2M ago

PMN

Analyst Reiterates Buy on ProMIS Neurosciences, Maintaining $35 Price Target Amid Strong Cash Position and PMN310 Clinical Progress

ProMIS Neurosciences, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from...

2M ago

PMN

PMN Earnings this Week: How Will it Perform?

ProMIS Neurosciences Inc. (PMN) is scheduled to report 2nd quarter earnings on 08/13/2026, after the market closes. Regarding...

3M ago

PMN

PMN310’s Clean Safety and Promising Biomarkers Drive Buy Rating; $35 Price Target Reiterated

In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on ProMIS Neurosciences, with...

3M ago

PMN

ProMIS Neurosciences price target raised to $69 from $35 at Guggenheim

Guggenheim raised the firm’s price target on ProMIS Neurosciences (PMN) to $69 from $35 and keeps a Buy...

3M ago

PMN

ProMIS Neurosciences price target raised to $33 from $20 at Chardan

Chardan analyst Keay Nakae raised the firm’s price target on ProMIS Neurosciences (PMN) to $33 from $20 and...

3M ago

PMN

ProMIS Neurosciences price target raised to $69 from $35 at Guggenheim

Guggenheim raised the firm’s price target on ProMIS Neurosciences (PMN) to $69 from $35 and keeps a Buy...

3M ago

PMN

ProMIS Reports Positive Interim PMN310 Alzheimer’s Trial Data

An announcement from ProMIS Neurosciences ( ($PMN) ) is now available. On July 28, 2026, ProMIS Neurosciences reported...

3M ago

PMN

ProMIS Neurosciences’ PMN310 shows positive result in Alzheimer’s Phase 1b trial

ProMIS Neurosciences (PMN) announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Phase 1b trial...

3M ago

PMN

ProMIS Neurosciences initiated with a Buy at Chardan

Chardan analyst Keay Nakae initiated coverage of ProMIS Neurosciences (PMN) with a Buy rating and $20 price target...

3M ago

PMN

Buy Rating Reiterated on PMN310’s Promising Phase 1a Data and Unchanged $18 Price Target

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on PMN stock, giving a Buy rating on...

3M ago

PMN

23J FAQ

What was ProMIS Neurosciences’s price range in the past 12 months?

ProMIS Neurosciences lowest stock price was €5.68 and its highest was €22.00 in the past 12 months.

What is ProMIS Neurosciences’s market cap?

ProMIS Neurosciences’s market cap is €64.70M.

When is ProMIS Neurosciences’s upcoming earnings report date?

ProMIS Neurosciences’s upcoming earnings report date is Nov 18, 2026 which is in 22 days.

How were ProMIS Neurosciences’s earnings last quarter?

ProMIS Neurosciences released its earnings results on Aug 13, 2026. The company reported -€1.142 earnings per share for the quarter, beating the consensus estimate of -€1.23 by €0.088.

Is ProMIS Neurosciences overvalued?

According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ProMIS Neurosciences pay dividends?

ProMIS Neurosciences does not currently pay dividends.

What is ProMIS Neurosciences’s EPS estimate?

ProMIS Neurosciences’s EPS estimate is -1.11.

How many shares outstanding does ProMIS Neurosciences have?

ProMIS Neurosciences has 8,967,693 shares outstanding.

What happened to ProMIS Neurosciences’s price movement after its last earnings report?

ProMIS Neurosciences reported an EPS of -€1.142 in its last earnings report, beating expectations of -€1.23. Following the earnings report the stock price went up 3.333%.

Which hedge fund is a major shareholder of ProMIS Neurosciences?

Currently, no hedge funds are holding shares in DE:23J

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

ProMIS Neurosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-143.09%

Trailing 12-Months

Asset Growth

496.18%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

ProMIS Neurosciences

ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.

ProMIS Neurosciences (23J) Earnings & Revenues

Historic Earnings Reports

23J Earnings Call

Q2 2026

0:00 / 0:00

23J Stock 12 Month Forecast

Average Price Target

€38.32

▲(214.08% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"€5","90":"€90","26.25":"€26.3","47.5":"€47.5","68.75":"€68.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":89.110993,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€89.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.31772699,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€38.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.03997874,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€16.04</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,26.25,47.5,68.75,90],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.1,15.254691769230769,21.40938353846154,27.564075307692306,33.71876707692308,39.873458846153845,46.02815061538462,52.18284238461539,58.33753415384616,64.49222592307692,70.6469176923077,76.80160946153846,82.95630123076923,{"y":89.110993,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.1,11.34751746076923,13.59503492153846,15.84255238230769,18.090069843076922,20.337587303846153,22.58510476461538,24.83262222538461,27.080139686153842,29.327657146923073,31.575174607692304,33.822692068461535,36.070209529230766,{"y":38.31772699,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.1,9.633844518461538,10.167689036923075,10.701533555384614,11.235378073846153,11.769222592307692,12.30306711076923,12.836911629230768,13.370756147692306,13.904600666153845,14.438445184615382,14.972289703076921,15.50613422153846,{"y":16.03997874,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.099,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.12,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.95,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.9,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >